title: [Efficacy of adoptive immunotherapy after mixed hematopoietic stem cell transplantation on acute myeloid leukemia].
abstract: The purpose of this study was to investigate the efficacy of treatment with haploidentical donor's lymphocyte infusion(hiDLI) combined with interleukin-2 (IL-2) after transplantation of autologous peripheral blood stem cells mixed with haploidentical allogeneic bone marrow (mix-HSCT) for acute myeloid leukemia (AML). 49 patients diagnosed as AML were enrolled in this study. After preconditioning with TBI plus VEMAC regimen, all patients received mix-HSCT. Autologous peripheral blood hematopoietic stem cells were mobilized with chemotherapy-combined G-CSF, and haploidentical allogeneic bone marrow cells were not mobilized with G-CSF. 33 patients in test group were treated with hiDLI plus IL-2 for 1-8 times after hematopoietic reconstruction, 16 patients in control group received mix-HSCT only. All the patients were followed-up for more than 3 years. The results showed that all the patients obtained hematopoietic reconstruction, and no graft-versus-host disease (GVHD) was found. In two groups, the median time of absolute neutrophil count (ANC) ≥ 0.5×10(9)/L was 14 (12 - 18) and 14 (11 - 16) days, and WBC count ≥ 4.0×10(9)/L was 17 (16 - 22) and 18(17 - 20) days, Plt count ≥ 50×10(8)/L were 25 (24 - 29) and 25 (23 - 26) days. 9 patients in test group formed mixed chimerism (46XX/46XY) and sustained about 3 - 12 months; disease-free survival (DFS) was 63.6%, 3 patients in control group formed mixed chimerism (46XX/46XY), persistent about 3-6 months; DFS was 50.0%. It is concluded that treatment with hiDLI plus IL-2 after mix-HSCT for AML patients may increase DFS efficiently.
authors.affiliation: Department of Hematology, Lanzhou General Hospital, Gansu Province, China.
authors.forename: Cun-Bang
authors.initials: CB
authors.lastname: Wang
authors.forename: Hai
authors.initials: H
authors.lastname: Bai
authors.forename: Rui
authors.initials: R
authors.lastname: Xi
authors.forename: Yao-Zhu
authors.initials: YZ
authors.lastname: Pan
authors.forename: Qian
authors.initials: Q
authors.lastname: Zhang
authors.forename: Jin-Mao
authors.initials: JM
authors.lastname: Zhou
authors.forename: Tao
authors.initials: T
authors.lastname: Wu
authors.forename: Shu-Fen
authors.initials: SF
authors.lastname: Xu
mesh_terms: D000293:Adolescent; D000328:Adult; D005260:Female; D019650:Hematopoietic Stem Cell Mobilization; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016219:Immunotherapy, Adoptive; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D008297:Male; D014184:Transplantation, Homologous; D055815:Young Adult